For Luminal B BC cases (ER-positive and/or PgR-positive and Human Epidermal Growth Factor Receptor Type 2 (HER-2)-negative), standard therapy is an association between ET and chemotherapy (ChT). This evidence concerns the gene ERBB2 and breast cancer.